Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.
Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen.
It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.
US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.